183490.KQ

Enzychem Lifesciences Corporation [183490.KQ] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

183490.KQ Stock Summary

In the News

183490.KQ Financial details

Company Rating
-
Market Cap
151.84B
Income
-9.33B
Revenue
76.04B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
113
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-8.08
Forward P/E
-
PEG
1.23
P/S
3.26
P/B
0.75
P/C
-
P/FCF
-9.14
Quick Ratio
14.47
Current Ratio
16.04
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-109.82
EPS next Y
-
EPS next Q
-
EPS this Y
-65.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-17.33%
Revenue last 5Y
19.3%
Revenue Q/Q
17.43%
EPS Q/Q
-30.45%
-
-
-
-
SMA20
-15.16%
SMA50
-29.96%
SMA100
-2.57%
Inst Own
-
Inst Trans
-
ROA
-9%
ROE
-9%
ROC
-0.07%
Gross Margin
8%
Oper. Margin
-30%
Profit Margin
-40%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1110.0-2220.0
52W High
-55.41%
52W Low
-10.81%
RSI
39
Rel Volume
1.95
Avg Volume
346.68K
Volume
677.47K
Perf Week
-7.13%
Perf Month
-19.9%
Perf Quarter
-
Perf Half Y
-13.61%
-
-
-
-
Beta
1.462
-
-
Volatility
16.12%, 95.28%
Prev Close
0%
Price
990
Change
-1.3%

Something similar

Top by Market Cap
CMC.DE
GOOGL
MSF.DE
AAPL
APC.DE
Same Sector
0RRB.L
BIO.WA
1931.HK
OPTI.L
002693.SZ
Same Price Range
STAN.L
SBIN.NS
3984.T
7245.T
MFSL.NS
Similar Market Cap
LATO-B.ST
CSLLY
601111.SS
NATCOPHARM.NS
ROUTE.NS

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 346.68K
  • Market Capitalization 151.84B
  • Employee 113
  • CEO Ki-Young Sohn
  • Headquarters Seoul,KR
  • IPO Date 2017-04-05
  • Website http://www.enzychem.com

Enzychem Lifesciences Corporation, a pharmaceutical company, focuses on the development of oral small molecule therapies for patients with unmet medical needs for oncology, metabolic diseases, and inflammatory diseases in South Korea. It is also developing potential therapies based on EC-18 technology platform to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, and acute radiation syndrome. The company was founded in 1999 and is headquartered in Seoul, South Korea.